Navigation Links
Dismissed leukemia drug helps cll patients, studies show
Date:12/7/2008

COLUMBUS, Ohio A drug once dismissed as ineffective in patients with chronic lymphocytic leukemia (CLL) has shown promising results in two phase I and II clinical trials, according to researchers at The Ohio State University Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute.

Together, the trials involved 116 patients with advanced CLL who were treated with the drug flavopiridol (alvocidib). Responses were seen in approximately half of patients, many of whom had chromosomal abnormalities that made it unlikely they would be helped by standard therapies.

"Ohio State's success has reinvigorated interest in flavopiridol at the National Cancer Institute and other cancer centers," says Dr. Thomas Lin, a researcher and oncologist at Ohio State's Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute.

Lin, the study's first author and a member of the Experimental Therapeutics program at Ohio State's Comprehensive Cancer Center, will discuss the findings during the 50th Annual Meeting of the American Society of Hematology (ASH). Lin will explain the research during the ASH-ASCO Joint Symposium on Sunday morning (12/7), and later that day during an oral presentation on CLL therapy.

Earlier this year at the annual meeting of the American Society of Clinical Oncology, Ohio State investigators made an oral presentation on a phase II study of 64 patients treated with flavopiridol. The novel drug is effective in resistant CLL that does not respond to other therapies. Each year, ASH selects five ASCO abstracts to be featured during the Joint Symposium.

Chronic lymphocytic leukemia is the most common type of adult leukemia, with some 15,000 new cases this year. While therapy has improved, CLL remains incurable and patients often suffer significant infections as a consequence of the disease and treatment.

In the 1980s, animal tests showed flavopiridol to be a potent cancer-fighter. But when researchers gave it to humans in repeated trials using a continuous prolonged infusion, the drug proved ineffective and was essentially forgotten.

What wasn't known then and what Ohio State researchers discovered later is that flavopiridol binds to proteins in human blood, which ties up much of the available drug and leaves less free drug in the bloodstream to kill cancer cells. In essence, patients were not getting enough of the drug to be effective.

Researchers at Ohio State devised a new dosing schedule for the drug to increase its anti-tumor activity.

The new schedule increased the drug's blood level enough to kill cancer cells in humans, says Dr. Michael Grever, chairman of the department of internal medicine and co-leader of the Experimental Therapeutics program at Ohio State's Comprehensive Cancer Center.

"Flavopiridol has bridged the way for several CLL patients to receive a curative stem cell transplant," says Dr. John Byrd, associate director of translational research and principal investigator of the phase II trial. Ohio State is now participating in a multi-center flavopiridol trial to see if other cancer centers have similar results with flavopiridol.


'/>"/>

Contact: Eileen Scahill
Eileen.Scahill@osumc.edu
614-390-9832
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
2. Study finds heart failure is rare among leukemia patients on imatinib
3. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. Novel strategy under study for aggressive leukemia
7. Drug has ability to cure type of leukemia
8. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
9. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
10. Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
11. St. Jude Finds Anti-Leukemia Drug Increases Patient Fatigue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board of ... Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve ... Puffer’s retirement at the end of 2018. Upon assuming the role of President and ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology: